This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fecher, L. A. Articles by Alani, R. M. Search for Related Content PubMed PubMed Citation Articles by Fecher, L. A. Articles by Alani, R. M. Social Bookmarking                            What's this?

Toward a Molecular Classification of Melanoma

Leslie A. Fecher, Staci D. Cummings, Megan J. Keefe, Rhoda M. Alani

From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and the Departments of Oncology and Pharmacology and Molecular Sciences, Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Address reprint requests to Rhoda M. Alani, MD, Johns Hopkins University School of Medicine, 1650 Orleans St, CRB 342, Baltimore, MD 21231-1000; e-mail: ralani{at}jhmi.edu

The incidence of melanoma is increasing at one of the highest rates of any form of cancer in the United States, with the current lifetime risk being one in 68. At present, there are limited systemic therapies to treat advanced stages of melanoma, and the key to improved survival remains early detection. Recent discoveries have allowed for a clearer picture of the molecular events leading to melanoma development and progression. Since identifying prevalent activating mutations of the BRAF kinase in melanomas, there has been a flood of additional molecular studies to further clarify the role of this pathway and others in melanomagenesis. In particular, recent genetic studies have demonstrated specific genotype-phenotype correlations that provide the first major insights into the molecular subclassification of melanoma and the heterogeneous nature of this malignancy. In this article, we review the most up-to-date molecular discoveries in melanoma biology and provide a framework for understanding their significance in melanoma development and progression. We also provide details on the development of novel therapies based on these recent molecular discoveries and insight into current and planned clinical trials. It is expected that these latest studies in melanoma will help define the critical molecular events involved in disease onset and progression and allow us to move rapidly toward a true molecular classification. We eagerly anticipate rationally designed melanoma therapies based on such a classification scheme and the associated improvements in patient outcomes.

Supported by Grant No. CA107017 from the National Cancer Institute, the Flight Attendant Medical Research Institute, and the Joanna M. Nicolay Melanoma Foundation.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Oka, N. Sumita, M. Sakaguchi, T. Iwasaki, T. Bito, T. Kageshita, K.-i. Sato, Y. Fukami, and C. Nishigori 12-O-Tetradecanoylphorbol-13-acetate Inhibits Melanoma Growth by Inactivation of STAT3 through Protein Kinase C-activated Tyrosine Phosphatase(s) J. Biol. Chem., October 30, 2009; 284(44): 30416 - 30423. [Abstract] [Full Text] [PDF]

				P. Hersey, L. Bastholt, V. Chiarion-Sileni, G. Cinat, R. Dummer, A. M. M. Eggermont, E. Espinosa, A. Hauschild, I. Quirt, C. Robert, et al. Small molecules and targeted therapies in distant metastatic disease Ann. Onc., August 1, 2009; 20(suppl_6): vi35 - vi40. [Abstract] [Full Text] [PDF]

				K. A. Chernoff, L. Bordone, B. Horst, K. Simon, W. Twadell, K. Lee, J. A. Cohen, S. Wang, D. N. Silvers, G. Brunner, et al. GAB2 Amplifications Refine Molecular Classification of Melanoma Clin. Cancer Res., July 1, 2009; 15(13): 4288 - 4291. [Abstract] [Full Text] [PDF]

				A. Hauschild, S. S. Agarwala, U. Trefzer, D. Hogg, C. Robert, P. Hersey, A. Eggermont, S. Grabbe, R. Gonzalez, J. Gille, et al. Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma J. Clin. Oncol., June 10, 2009; 27(17): 2823 - 2830. [Abstract] [Full Text] [PDF]

				D. A. Solomon, J.-S. Kim, J. C. Cronin, Z. Sibenaller, T. Ryken, S. A. Rosenberg, H. Ressom, W. Jean, D. Bigner, H. Yan, et al. Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma Cancer Res., December 15, 2008; 68(24): 10300 - 10306. [Abstract] [Full Text] [PDF]

				D. B. Solit, I. Osman, D. Polsky, K. S. Panageas, A. Daud, J. S. Goydos, J. Teitcher, J. D. Wolchok, F. J. Germino, S. E. Krown, et al. Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma Clin. Cancer Res., December 15, 2008; 14(24): 8302 - 8307. [Abstract] [Full Text] [PDF]

				J. Poust Targeting metastatic melanoma Am. J. Health Syst. Pharm., December 15, 2008; 65(24_Supplement_9): S9 - S15. [Abstract] [Full Text] [PDF]

				X. Jiang, J. Zhou, N. K. Yuen, C. L. Corless, M. C. Heinrich, J. A. Fletcher, G. D. Demetri, H. R. Widlund, D. E. Fisher, and F. S. Hodi Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma Clin. Cancer Res., December 1, 2008; 14(23): 7726 - 7732. [Abstract] [Full Text] [PDF]

				C. Beadling, E. Jacobson-Dunlop, F. S. Hodi, C. Le, A. Warrick, J. Patterson, A. Town, A. Harlow, F. Cruz III, S. Azar, et al. KIT Gene Mutations and Copy Number in Melanoma Subtypes Clin. Cancer Res., November 1, 2008; 14(21): 6821 - 6828. [Abstract] [Full Text] [PDF]

				T. John, M. A. Black, T. T. Toro, D. Leader, C. A. Gedye, I. D. Davis, P. J. Guilford, and J. S. Cebon Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma Clin. Cancer Res., August 15, 2008; 14(16): 5173 - 5180. [Abstract] [Full Text] [PDF]

				M. Reschke, D. Mihic-Probst, E. H. van der Horst, P. Knyazev, P. J. Wild, M. Hutterer, S. Meyer, R. Dummer, H. Moch, and A. Ullrich HER3 Is a Determinant for Poor Prognosis in Melanoma Clin. Cancer Res., August 15, 2008; 14(16): 5188 - 5197. [Abstract] [Full Text] [PDF]

				D. L. Sheridan, Y. Kong, S. A. Parker, K. N. Dalby, and B. E. Turk Substrate Discrimination among Mitogen-activated Protein Kinases through Distinct Docking Sequence Motifs J. Biol. Chem., July 11, 2008; 283(28): 19511 - 19520. [Abstract] [Full Text] [PDF]

				F. S. Hodi, P. Friedlander, C. L. Corless, M. C. Heinrich, S. Mac Rae, A. Kruse, J. Jagannathan, A. D. Van den Abbeele, E. F. Velazquez, G. D. Demetri, et al. Major Response to Imatinib Mesylate in KIT-Mutated Melanoma J. Clin. Oncol., April 20, 2008; 26(12): 2046 - 2051. [Full Text] [PDF]

				F. L. Meyskens Jr. and M. Berwick UV or Not UV: Metals Are The Answer Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 268 - 270. [Full Text] [PDF]